Market Currents
More from Oncology conference: Myriad Genetics' (MYGN) lung cancer prognosis test significantly...
-
Monday, June 4, 2012, 8:57 AM ETMore from Oncology conference: Myriad Genetics' (MYGN) lung cancer prognosis test significantly predicts cancer-specific death in early stage adenocarcinoma lung cancer patients, a trial of 381 people shows. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
